Clinical trials: Graves Disease, open to volunteers
Graves Disease, Graves Disease (Basedow's Disease)
Prophylactic Treatment of Graves Ophthalmopathy (GO) in Newly Diagnosed Graves' Disease (GD) With Atorvastatin (ATORGO)
Graves' disease is an autoimmune condition that causes an overactive thyroid. Some people with Graves' disease develop thyroid eye disease, also called Graves' orbitopathy, which can cause swelling around the eyes, eye…
- Conditions
- Graves Disease, Graves Disease (Basedow's Disease), Graves Orbitopathy, Graves Ophthalmopathy
- Trial name
- ATORGO (NCT07883356)
- Testing
- Atorvastatin
- Where
- 7 sites in Sweden
- Volunteers
- 554 people
- Sponsor
- Region Skane
Safety, Tolerability
A Study of GenSci098 in Subjects With Active Thyroid Eye Disease
To evaluate the safety and tolerability of single and multiple ascending subcutaneous doses of GenSci098 in patients with thyroid eye disease (TED)
- Conditions
- Safety, Tolerability, GenSci098, Thyroid Eye Disease (TED)
- Trial name
- NCT06569758
- Testing
- GenSci098
- Where
- China
- Volunteers
- 76 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Graves Disease
Study of BHV-1300 in Graves' Disease
The purpose of this study is to determine if BHV-1300 is a safe treatment in participants with Graves' Disease and to explore its effect on disease-specific biomarkers.
- Trial name
- NCT06980649
- Testing
- BHV-1300
- Where
- 18 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Biohaven Therapeutics Ltd.
Thyroid Eye Disease (TED)
Open-Label Extension Study of MHB018A in Subjects With Thyroid Eye Disease
This is a multicenter, open-label extension (OLE) study of MHB018A in subjects with moderate-to-severe TED.
- Trial name
- NCT07262476
- Testing
- MHB018A injection
- Where
- China
- Volunteers
- 258 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Graves Ophthalmopathy, Thyroid Associated Ophthalmopathy
Treatment of Graves´ophthalmopathy with Simvastatin (GO-S)
In an investigator initiated multicenter trial (Malmö, Odense, Århus) the investigators aim at evaluating activity of Graves´ophthalmopathy (GO) and progress to severe GO in patients with mild to moderate Graves´ ophthalmopathy…
- Conditions
- Graves Ophthalmopathy, Thyroid Associated Ophthalmopathy, Thyroid Associated Orbitopathy
- Trial name
- NCT03131726
- Testing
- Simvastatin 40mg
- Where
- Sweden
- Volunteers
- 80 people
- Sponsor
- Lund University
Thyroid Eye Disease
A Phase III Study of KHN939 in Chinese Patients With Moderate-to-Severe Inactive Thyroid Eye Disease
This is a multicenter, randomized, double-masked, placebo-controlled Phase 3 study to evaluate the efficacy, safety, immunogenicity, and population pharmacokinetic (PopPK) characteristics of KHN939 in Chinese patients with…
- Trial name
- Halo-2 (NCT07720648)
- Testing
- KHN939
- Where
- China
- Volunteers
- 117 people
- Sponsor
- Beijing Kanghong Biological Medicine Co., Ltd.
Graves' Disease
A Study to Learn About The Effects of Felzartamab on Thyroid Function and Its Safety in Adults With Graves' Disease Ages 18 to 75 Years Old
In this study, researchers will learn more about the use of felzartamab in participants with Graves' Disease, also known as GD. GD is an autoimmune disease, which means the body's immune system attacks its own healthy cells.
- Trial name
- GRAVITATE (NCT07722546)
- Testing
- Felzartamab
- Where
- 14 sites in United States, Puerto Rico
- Volunteers
- 60 people
- Sponsor
- Biogen
Thyroid Eye Disease
An Open-Label Trial of Veligrotug in Participants With Thyroid Eye Disease Who Previously Responded to Teprotumumab
This is a clinical trial to evaluate the safety and efficacy of veligrotug (LUMVOA™) in participants with moderate to severe TED who previously received and responded to an initial course of teprotumumab treatment but…
- Trial name
- NCT07832136
- Testing
- veligrotrug (LUMVOA™)
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- Viridian Therapeutics, Inc.
Thyroid-Associated Ophthalmopathy
A Study on the Combined Use of Tocilizumab and Flupentixol-Melitracen in the Treatment of Thyroid-Associated Ophthalmopathy
Thyroid-associated ophthalmopathy (TAO) is a serious, progressive, vision-threatening autoimmune disease that can be categorized into mild, moderate, and severe stages based on severity.
- Trial name
- NCT06927375
- Testing
- Tocilizumab(400mg) combined with Flupentixol Melitracen(0.5mg:10mg), Tocilizumab(400mg)
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Graves Ophthalmopathy
Bimatoprost as a Treatment for Graves' Orbitopathy
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
- Trial name
- NCT03708627
- Testing
- Bimatoprost Ophthalmic
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Johns Hopkins University
Thyroid Eye Disease, TED, Graves Orbitopathy
Study to Assess Linsitinib in Participants With Moderate to Severe Active Thyroid Eye Disease (TED)
The goal of this clinical trial is to evaluate the efficacy, safety, and tolerability of linsitinib in participants with moderate to severe Thyroid Eye Disease (TED).
- Trial name
- ORBIT (NCT07753603)
- Testing
- linsitinib
- Where
- 18 sites in United States
- Volunteers
- 130 people
- Sponsor
- Sling Therapeutics, Inc.
Graves Ophthalmopathy
A Randomized Clinical Trial of Intravenous Methylprednisolone With 2 Protocols in Patients With Graves Orbitopathy
Intravenous glucocorticoid (IVGC) is an accessible and effective therapy for Graves orbitopathy (GO); the 4.5-g weekly protocol is well studied, but many details of treatment protocols need to be clarified.
- Trial name
- NCT06510114
- Testing
- methylprednisolone(daily scheme), methylprednisolone(weekly scheme)
- Volunteers
- 150 people
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Thyroid Eye Disease
A Study of Teprotumumab N01 in Subjects With Active Thyroid Eye Disease
This is a multicenter, randomized, open-label, active-controlled Phase IV clinical trial in participants with active thyroid eye disease (TED).
- Trial name
- NCT07265258
- Testing
- Teprotumumab N01, Methylprednisolone
- Where
- China
- Volunteers
- 92 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Thyroid Associated Ophthalmopathy
Multi-model Image of Doxycycline in TAO
This study aims to evaluate the efficacy of doxycycline treating Thyroid Associated Ophthalmopathy by multi-modal image.
- Trial name
- NCT05112211
- Testing
- Doxycycline Hyclate
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sun Yat-sen University
Thyroid Eye Disease
An Open-label, Rollover Trial to Evaluate the Efficacy and Safety of AMG 732 in Participants With Thyroid Eye Disease
The main objective of this trial is to assess the efficacy of AMG 732 in participants with thyroid eye disease (TED) who are defined as primary nonresponders or relapsed during the safety follow-up in the parent trial…
- Trial name
- HAZEL 401 (NCT07438405)
- Testing
- AMG 732
- Where
- 8 sites in United States, Poland and 2 more
- Volunteers
- 30 people
- Sponsor
- Amgen
Safety, Tolerability
A Study of GensSci098 in Subjects With Graves' Disease
To evaluate the safety and tolerability of single ascending subcutaneous doses of GenSci098 in patients with Graves' Disease
- Conditions
- Safety, Tolerability, GenSci098, Graves Disease
- Trial name
- NCT07286656
- Testing
- GenSci098
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
Graves Disease, Hyperthyroidism/Thyrotoxicosis
Evaluating an AI Tool for Detecting Thyrotoxic States
This observational study aims to evaluate the performance of a software-based medical device, Glandy HYPER, in detecting the thyrotoxic state in patients with hyperthyroidism.
- Trial name
- NCT07017907
- Testing
- Heart rate-based AI software for detecting thyrotoxicosis
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- THYROSCOPE INC.
Basedow Disease
Describe the Progression of Inflammatory Orbitopathy and the Biological Progression of Patients Receiving Second-line Treatment
Describe the progression of inflammatory orbitopathy and the biological progression of patients receiving second-line treatment (immunosuppressants, radiotherapy, or biotherapy).
- Trial name
- HZN-IIT (NCT07117981)
- Where
- 9 sites in France
- Volunteers
- 100 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Graves Disease, Thyroid Cancer
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone levels are intentionally changed by treatment.
- Trial name
- NCT07410637
- Testing
- Oral Glucose Tolerance Test
- Where
- Germany
- Volunteers
- 60 people
- Sponsor
- University of Ulm
Graves Disease, Relapse
Effects of Different Treatment Schemes on the Regulation and Recurrence of Graves' Disease
In this study, the dose of methimazole was adjusted according to the different states of thyroid function, and the effects of conventional therapy and intensive therapy on the cumulative recurrence of Graves' hyperthyroidism…
- Conditions
- Graves Disease, Relapse, Treatment, Drug Withdrawal
- Trial name
- NCT05461820
- Testing
- Methimazole
- Where
- China
- Volunteers
- 240 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University